We recently expressed cautious support for the CMMI Geographic Direct Provider Contracting model in a letter to CMS. New opportunities for physician groups, health plans, and other organizations to partner to serve Medicare, and Medicare and Medicaid dual-eligible beneficiaries could bring new innovations in care delivery to more beneficiaries. As the number of alternative payment […]
The Hill: Is arbitration an answer for high drug prices?
You can read the published op-ed on The Hill here. Future prescription drug costs are projected to spike to unsustainable levels. Biologic pharmaceuticals will make up the majority of new drugs, and unfortunately, they are commonly priced at over five figures for a course of treatment. These drugs promise new breakthroughs in treatments for patients with certain […]
LA Times: Drug executives come to Washington as Republicans grapple with how to stop runaway prices
By NOAM N. LEVEY and JENNIFER HABERKORN In a much-anticipated piece of political theater, seven leading pharmaceutical executives appeared before a powerful Senate committee Tuesday for a grilling from lawmakers who pledged a historic bipartisan effort to rein in skyrocketing prescription drug prices. But even as drug prices have emerged as one of the few areas of common […]
The Seven Deadly Sins of the Prescription Drug Affordability Market
By: John Rother The problem of unaffordable prescription drug prices is not a simple on, nor is there a single policy that addresses the full range of issues. We need to fix the current broken system to make drugs more affordable while maintaining incentives to discover important new cures. There are seven “deadly sins” that now characterize […]
WSJ: Would Drug Price Controls Kill Innovation?
The original letter to the editor was published on January 15, 2018 and can be found here. The article in which the letter responds to can be found here. By John Rother The U.S. is alone among developed nations in failing to assure more affordable medications for its citizens. Medicare trustees have an obligation to act prudently to obtain fair prices for beneficiaries. Recent research has […]